Benjamin Harshbarger's Net Worth
$8.49 Thousand
Who is Benjamin Harshbarger?
Benjamin Harshbarger does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include QLT INC/BC, Astria Therapeutics, Inc., and Aegerion Pharmaceuticals, Inc..
SEC CIK
Benjamin Harshbarger's CIK is 0001653133
Past Insider Trading and Trends
2016 was Benjamin Harshbarger's most active year for acquiring shares with 8 total transactions. Benjamin Harshbarger's most active month to acquire stocks was the month of October. 2017 was Benjamin Harshbarger's most active year for disposing of shares, totalling 10 transactions. Benjamin Harshbarger's most active month to dispose stocks was the month of April. 2021 saw Benjamin Harshbarger paying a total of $0.00 for 600,000 shares, this is the most they've acquired in one year. In 2017 Benjamin Harshbarger cashed out on 2,588 shares for a total of $5,669.22, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
QLT INC/BC No price found
See RemarksBenjamin Harshbarger owns 1,747 units of Common Shares, without par value, 1,673 units of Common Shares and 3,683 units of Common Stock. In the year 2016 Benjamin Harshbarger filed a total of 12 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -5.44% | -212.00 |
$1.22 | -$258.64 | 3.68K |
May 9
| |||
Form 4
| -12.77% | -570.00 |
$4.18 | -$2,380.34 | 3.9K |
May 9 - Sep 17
| |||
Form 4
| -1.15% | -52.00 |
$3.50 | -$182.00 | 4.46K |
Apr 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 6
| |||
Form 4
| +15.78% | 228 |
$7.08 | -$771.72 | 1.67K |
Sep 17
| |||
Form 4
| +50.52% | 485 |
$8.97 | -$2,081.04 | 1.45K |
May 15
| |||
Form 4
| +104.26% | 490 |
$9.42 | -$2,204.28 | 960 |
May 9
| |||
Form 4
| +34.67% | 121 |
$10.74 | -$612.18 | 470 |
Apr 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 22
| |||
Form 4
|
∞
| 1.75K |
—
|
—
| 1.75K |
Nov 29
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Astria Therapeutics, Inc. (ATXS) Snapshot price: $11.12
Chief Legal Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Aegerion Pharmaceuticals, Inc. No price found
General Counsel and Secretary
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||